The Global Biosimilars Market is Predict to reach $59 Billion by 2028, at a CAGR of 24.4%
Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Biosimilars Market Growth, Trends and Report Highlights
According to a new report, published by KBV research, The Global Biosimilars Market size is expected to reach $59 billion by 2028, rising at a market growth of 24.4% CAGR during the forecast period.
The Oncology Diseases market is leading the Global Biosimilars Market by Application in 2021, thereby, achieving a market value of $25.2 billion by 2028. This dominance is due to the rise in the incidence of cancer and other oncology diseases such as pancreatic neuroendocrine tumors. Due to the complexity of the biology & behavior of well-differentiated neuroendocrine tumors (NETs), biosimilars play a crucial role in their clinical management.
The Granulocyte-Colony Stimulating Factor market is experiencing a CAGR of 24.1% during (2022 - 2028). Granulocyte colony-stimulating factor is administered to patients with specific cancers, neutropenia resulting from specific types of chemotherapy, and severe chronic neutropenia unrelated to cancer treatment. In addition, Granulocyte colony-stimulating factor aids in the production of more white blood cells in the bone marrow, due to which the biosimilars market would expand in this segment.
The North America market dominated the Global Biosimilars Market by Region in 2021, thereby, achieving a market value of $22.1 billion by 2028. The Europe market is exhibiting a CAGR of 23.6% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 25.4% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/biosimilars-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA
Global Biosimilars Market Segmentation
By Application
- Oncology Diseases
- Blood Disorders
- Chronic & Autoimmune Diseases
- Others
By Type
- Monoclonal Antibodies
- Granulocyte-Colony Stimulating Factor
- Erythropoietin
- Human Growth Hormone
- Insulin
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Amgen, Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Intas Pharmaceutical Ltd
- Novartis AG (Sandoz)
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Fresenius SE & Co. KGaA
Related Reports:
North America Biosimilars Market Size, Share & Forecast, 2028
- August-2022
- 91 Pages
LAMEA Biosimilars Market Size, Share & Industry Growth, 2028
- August-2022
- 98 Pages
Europe Biosimilars Market Size, Share & Outlook Trends, 2028
- August-2022
- 99 Pages
Asia Pacific Biosimilars Market Size, Share & Analysis, 2028
- August-2022
- 99 Pages